Mabworks

Beijixin (MIL62, generic name: Ocrelizumab β Injection) is a third-generation CD20 antibody with a unique market position, approved in China (National Drug Approval No. S20260011) for treating NMOSD and primary membranous nephropathy (pMN), making it the first globally approved therapy for pMN and the first domestically approved NMOSD drug in China.

Tianguan Real Biotech provides monoclonal antibody drugs and biopharmaceutical research and production services, supporting the full process from molecule to commercialization.

Tianguan Real Biotech’s core technology platform covers antibody discovery, cell line development, process scaling, and quality analysis to accelerate antibody drug development.

In April 2021, Beijing Tianguo Real Biotech initiated a phase Ⅱ clinical trial for MIL86, a recombinant fully human monoclonal antibody, to evaluate safety, tolerability, and efficacy in treating primary hyperlipidemia.

The expert interpretation section provides professional insights into Tianguo Real’s innovative antibody drugs, including clinical research progress and academic interpretations of Beijiexin (Otorituxan β) for NMOSD and primary membranous nephropathy.

Tianguo Real Pharmaceuticals’ news center covers company updates, R&D progress, and biopharmaceutical industry insights.

Tianguan Real Biotech recruits talent in the biopharmaceutical sector for roles in research and development, process engineering, and quality assurance.

The management team at Tianguo Real includes senior biopharmaceutical executives Li Feng and Chen Luning, chief medical officer.

Tianguo Real Pharmaceuticals’ MabWorks team specializes in antibody drug development and industrialization, with a complete R&D platform, process capabilities, and quality system.

Tianguan Real Biotech offers antibody drug development and production partnerships, as well as CDMO services for biologics.

Tianguan Real Biotech (MabWorks) focuses on discovering and developing innovative and differentiated antibody drugs, with its core product Beijixin (Ocrelizumab β Injection, MIL62) being a glycosylated third-generation humanized CD20 monoclonal antibody approved in China (National Drug Approval No. S20260011) for NMOSD and pMN. The company also has bispecific and trispecific antibody pipelines.